Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (2)

Search Parameters:
Keywords = transdermal flunixin meglumine

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
15 pages, 5968 KB  
Article
Transdermal Flunixin Meglumine as a Pain Relief in Donkeys: A Pharmacokinetics Pilot Study
by Amy K. McLean, Tara Falt, Essam M. Abdelfattah, Brittany Middlebrooks, Sophie Gretler, Sharon Spier, David Turoff, Francisco Javier Navas Gonzalez and Heather K. Knych
Metabolites 2023, 13(7), 776; https://doi.org/10.3390/metabo13070776 - 21 Jun 2023
Cited by 4 | Viewed by 3262
Abstract
Recent approval of transdermal flunixin meglumine (FM) (Banamine®) in cattle has opened the door for the drug’s potential application in other species. Transdermal FM could provide a safe and effective form of pain relief in donkeys. In order to evaluate the [...] Read more.
Recent approval of transdermal flunixin meglumine (FM) (Banamine®) in cattle has opened the door for the drug’s potential application in other species. Transdermal FM could provide a safe and effective form of pain relief in donkeys. In order to evaluate the pharmacokinetics and effects of FM on anti-inflammatory biomarkers in donkeys, a three-way crossover study design was employed. In total, 6 healthy donkeys were administered transdermal (TD) FM at a dosage of 3.3 mg/kg, and oral (PO) and intravenous (IV) doses of 1.1 mg/kg body weight. Blood samples were collected over 96 h to determine the concentration of flunixin, 5OH flunixin, and eicosanoids (TXB2 and PGF2 alpha) using LC-MS/MS. The results indicated that both flunixin and 5OH flunixin were detectable in blood samples collected during TD. The elimination of the drug was slower following the TD route compared to PO and IV. TD administration significantly decreased TXB2 levels in non-stimulated serum from 1 to 96 h post-administration, while IV and PO resulted in TXB2 reduction for 1 to 8 h. A significant reduction in PGF2 alpha was observed in PO and IV 1 h after administration, while TD resulted in a gradual decline from 4 to 72 h. The study concluded that the off-label use of transdermal FM at 3.3 mg/kg could be effective in controlling inflammation in donkeys. Full article
(This article belongs to the Section Pharmacology and Drug Metabolism)
Show Figures

Figure 1

12 pages, 1098 KB  
Article
Behavioral and Physiological Response to Routine Thermal Disbudding in Dairy Calves Treated with Transdermal Flunixin Meglumine
by Tara Gaab, Mary Wright and Meghann Pierdon
Animals 2022, 12(5), 533; https://doi.org/10.3390/ani12050533 - 22 Feb 2022
Cited by 3 | Viewed by 2715
Abstract
Transdermal flunixin meglumine was approved in 2018 to treat pain related to foot-rot in cattle, leading to the question of whether it would be effective as part of a comprehensive pain management strategy for disbudding. To investigate, calves were assigned to three treatment [...] Read more.
Transdermal flunixin meglumine was approved in 2018 to treat pain related to foot-rot in cattle, leading to the question of whether it would be effective as part of a comprehensive pain management strategy for disbudding. To investigate, calves were assigned to three treatment groups: 2% lidocaine cornual nerve block only (L), lidocaine nerve block +0.45 mg/lb (1 mg/kg) oral meloxicam (M), or lidocaine nerve block +1.5 mg/lb (3.3 mg/kg) transdermal flunixin meglumine (F) (n = 61). Ear flicking (p = 0.001), head shaking (p < 0.001), tail flicking (p < 0.001), interaction with the environment (p < 0.001), grooming (p < 0.01), posture changes (p < 0.05), and standing (p < 0.001) were impacted by the time relative to the procedure. Cortisol levels rose post procedure (p < 0.001). There was no difference in rates of behaviors or cortisol between treatments. These results indicate that calves showed alterations in behavior and cortisol in response to disbudding but not between treatments. We conclude that the pain management protocol for disbudding, which included transdermal flunixin meglumine with a lidocaine cornual nerve block, did not show significant differences from protocols using meloxicam with a lidocaine block, or a lidocaine block alone. Full article
(This article belongs to the Section Animal Welfare)
Show Figures

Figure 1

Back to TopTop